Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director

OSE Immunotherapeutics
Posted on: 16 Sep 16

Nantes, Paris, September 15, 2016 - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, today announces the appointment of Iris Pauporté as Clinical Project Director to reinforce the team’s scientific expertise.


OSE immunotherapeutics reinforces its clinical team with the appointment of Iris Pauporté as Clinical Project Director for the clinical development of Tedopi®, an innovative combination of neoepitopes developed in immuno-oncology. Iris will be leading the international registration Phase 3 clinical trial with Tedopi®, an innovative combination of neoepitopes developed in immuno-oncology in advanced lung cancer (NSCLC). She will also be involved in the preparation of a Phase 2 clinical trial considered in 2017 with Tedopi® combined with a checkpoint inhibitor, and in exploring Tedopi® in other cancer indications.


"We are very pleased to welcome Iris in our team. She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology. She will contribute to the development of our portfolio of products in immuno-oncology, ranging from research to the registration phase, with Effi-DEM, our new generation checkpoint inhibitor in preclinical stage and Tedopi® in Phase 3 registration clinical trial”, commented Alain Chatelin, Medical Director at OSE Immunotherapeutics.


Iris Pauporté holds a PhD in molecular biology and has more than 20 years’ experience in biomedical and clinical research, both in the pharmaceutical industry and at the French National Cancer Institute. Her expertise in coordinating large-scale scientific programs, coupled with her established relationships with many of the opinion leaders in oncology and immuno-oncology are major assets for the development of OSE Immunotherapeutics’ programs in immuno-oncology. Iris contributed to outstanding research projects and is a co-author of numerous publications in prestigious scientific journals.


Our ambition is to become a world leader in activation and regulation immunotherapies


OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.


The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:


ž   Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan Status in the US -  registration expected in 2019

ž   FR104, CD28-antagonist in immunotherapy - Phase 1 trial completed - targets autoimmune diseases and transplantation - licensed to J&J to pursue clinical development

ž   Effi-7, interleukin receptor 7 antagonist - in preclinical development for inflammatory bowel diseases and other autoimmune diseases

ž   Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-α receptor on the strategic CD47/SIRP- α pathway - in preclinical development for immuno-oncology

ž   R&D: candidates targeting new receptors in immuno-oncology

The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players, such as the one signed for FR104 with the J&J Group.

Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $ 67 billion in 2018 **.

There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales upper 10 billion $ for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.

Editor's Details

Mike Wood

Last updated on: 16/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.